Study of NTS071 for advanced solid tumors with TP53 Y220C mutation
Part of Cancer clinical trials.
This trial tests a new drug called NTS071 in people with advanced solid tumors that have a specific mutation in the TP53 gene (called Y220C). The goal is to see if the drug is safe and can help shrink or slow the growth of the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- Your cancer is advanced and has a specific mutation called TP53 Y220C
- You have already tried at least one previous cancer treatment and your cancer has gotten worse
- You have at least one tumor that can be measured on scans
- You are able to take care of yourself and are up and about most of the day
- Your major organs and bone marrow are working well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
This trial is testing a new tablet called YY2201 for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can help shrink or control the tumor.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug (called LG00313112) for people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug aims to target this change and may help slow or stop cancer growth.
This trial tests a new drug, GenSci128, for people whose solid tumors have a specific TP53 Y220C mutation. The drug aims to reactivate the p53 protein to fight cancer. It is for patients who have exhausted standard treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.